Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 258 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm May 20, 2021 EMA Recommends Extension of Therapeutic Indications for Rucaparib October 27, 2023 Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases July 10, 2024 Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... February 9, 2021 Load more HOT NEWS Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress New hormone treatment for advanced prostate cancer made available in England EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms
